# Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

> **NCT04935359** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 511 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** NIS793
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04935359
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-08-13
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04935359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04935359, "Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04935359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*